{"schema_version":"secwatch.filing_event.v1","accession":"0001357459-26-000017","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2026-08-10T20:18:21+00:00","discovered_at":"2026-08-10T20:19:00.879023+00:00","generated_at":"2026-08-10T20:19:11.344811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palisade Bio reports Q2 2026 net loss $10.6M; advances PALI-2108 into Phase 2","bullets":["Q2 2026 net loss $10.6M ($0.05/share) vs $2.8M ($0.58) year ago; R&D spend $7.4M vs $1.7M.","Cash $125.2M at June 30, 2026; funded through Phase 2 readouts (UC 2H 2027, CD early 2028).","Phase 1 PALI-2108: 5/5 UC clinical response, 2/5 remission; FSCD SES-CD reduced ~47.5% (3.8 points).","Phase 2 ASCENTRA-UC enrollment expected 2H 2026; ASCENTRA-CD IND expected 2H 2026, trial start 1Q 2027.","Board adds Robert Baltera and Jordan Zwick; $0.5M license revenue milestone from Newsoara."],"urls":{"canonical":"https://secwatch.observer/filing/0001357459-26-000017","json":"https://secwatch.observer/filing/0001357459-26-000017.json","markdown":"https://secwatch.observer/filing/0001357459-26-000017.md","text":"https://secwatch.observer/filing/0001357459-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/0001357459-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:19:11.344811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}